MARKET

RCKT

RCKT

Rocket Pharmaceu
NASDAQ
20.71
-0.23
-1.10%
Opening 14:05 05/29 EDT
OPEN
20.71
PREV CLOSE
20.94
HIGH
20.87
LOW
20.18
VOLUME
330.24K
TURNOVER
0
52 WEEK HIGH
32.53
52 WEEK LOW
14.89
MARKET CAP
1.88B
P/E (TTM)
-7.2228
1D
5D
1M
3M
1Y
5Y
Rocket Pharmaceuticals Enters Oversold Territory (RCKT)
NASDAQ · 1d ago
Weekly Report: what happened at RCKT last week (0520-0524)?
Weekly Report · 2d ago
Weekly Report: what happened at RCKT last week (0513-0517)?
Weekly Report · 05/20 10:57
Buy Rating on Rocket Pharmaceuticals Amidst Positive Outlook and Strategic Execution
Bank of America Securities analyst Jason Zemansky has maintained their bullish stance on RCKT stock. Rocket Pharmaceuticals (RCKT) has a PDUFA decision for Kresladi in treating LAD-1 expected in May. The company is developing a gene therapy for the treatment of Fanconi Anemia.
TipRanks · 05/20 00:05
Weekly Report: what happened at RCKT last week (0506-0510)?
Weekly Report · 05/13 11:05
Cantor picks 14 undervalued biotech stocks worth a second look
Healthcare Cantor picks 14 undervalued biotech stocks worth a second look. All of the picks were down more than 20% year-to-date, as of May 6. Cantor Fitzgerald has selected its 14 top picks for biotech stocks that it regards as significantly undervalued.
Seeking Alpha · 05/12 15:00
ROCKET PHARMACEUTICALS INC <RCKT.O>: UBS CUTS TARGET PRICE TO $51 FROM $54
Reuters · 05/10 14:13
Rocket Pharmaceuticals Presents Longer-Term Data Updates From Its Lentiviral Vector Hematology Portfolio At ASGCT
Long-term KRESLADI follow-up data demonstrate survival of 100% in the absence of stem cell transplantation from 18 to 45 months in patients with severe LAD-I. The drug has a well-tolerated safety profile in all nine patients.
Benzinga · 05/10 10:04
More
About RCKT
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.

Webull offers Rocket Pharmaceuticals Inc stock information, including NASDAQ: RCKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCKT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCKT stock methods without spending real money on the virtual paper trading platform.